Across TCGA pan-cancer cohorts, MIR606 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR606 data layer compared with 12 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher MIR606 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR606 expression acts as an unfavorable survival marker.
CESC are the cancer types where MIR606 Mutation most reproducibly stratifies survival.